2Barouch DH, Letvin NL, Seder RA. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev, 2004, 202 ( 1 ): 266-274.
3Chow YH, Huang WL, Chi WK, et al. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol, 1997, 71 ( 1 ): 169-178.
4Baluna R, Rizo J, Gordon BE, et al. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial ceils and initiating vascular leak syndrome. Proc Natl Acad Sci USA, 1999, 96 (3) : 3957-3962.
5Cai H, Yu DH, Tian X, et al. Cnadministration of interleukin 2 plasmid DNA with combined DNA vaccines significantly enhances the protective efficacy against Mycobacterium tuberculosis. DNA Cell Biol, 2005, 24( 10): 605-613.
6Arulanandam BP, Metzger DW. Modulation of mucosal and systemic immunity by intranasal interleukin-12 delivery. Vaccine, 1999, 17(3): 252-260.
7Buchanan JM, Vogel LA, Van Cleave VH, et al. Interleukin 12 alters the isotype-restricted antibody response of mice to hen egg white lysozyme. Int Immunol, 1995, 7 (9): 1519-1528.
8Buchanan RM, Arulanandam BP, Metzger DW. IL-12 enhances antibody responses to T-independent polysaccharide vaccines in the absence of T and NK cells. J Immunol, 1998, 161( 10): 5525-5533.
9Buchanan RM, Briles DE, Arulanandam BP, et al. IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine, 2001, 19 (15-16): 2020-2028.
10Arulanandam BP, Lynch JM, Briles DE, et al. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun, 2001, 69 ( 11 ): 6718-6724.
